Abbott, Tandem integrate 

ABBOTT PARK, Ill., and SAN DIEGO – Abbott and Tandem Diabetes Care have announced that the t:slim X2 insulin pump with Control-IQ technology is the first automated insulin delivery system to integrate with the newly available FreeStyle Libre 2 Plus sensor. For the first time, FreeStyle Libre technology users in the United States are now able to experience the therapeutic benefits of a hybrid closed-loop system that helps predict and prevent high and low blood sugar. “Tandem’s leadership in AID innovation is underscored with this milestone of launching the first insulin pump to be compatible with Abbott’s CGM technology in the U.S.,” said John Sheridan, president and CEO of Tandem Diabetes Care. “This represents another step forward in our commitment to provide customizable solutions to help reduce burden and create new possibilities for people living with diabetes.” Tandem’s t:slim X2 insulin pump connects wirelessly to the FreeStyle Libre 2 Plus sensor, which sends automatic glucose readings every minute to the pump. Users can conveniently see their minute-to-minute glucose data on the pump and accompanying t:connect mobile app. The pump’s Control-IQ technology predicts glucose levels 30 minutes into the future, automatically adjusting insulin delivery every five minutes based on CGM readings and can deliver automatic correction boluses (up to one per hour) to help prevent hyperglycemia. Tandem will email instructions to all in-warranty t:slim X2 users in the U.S., offering the option to add the new FreeStyle Libre 2 Plus sensor integration at no cost via remote software update. t:slim X2 pumps pre-loaded with the updated software are now shipping to new customers.